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Introduction
Methotrexate (MTX) is a folate antimetabolite used to treat 
malignancies and certain auto-immune diseases. In the pedi-
atric oncology population, neurotoxicity may occur after 
high doses of intravenous and standard doses of intrathecal 
MTX with a spectrum of manifestations ranging from 
asymptomatic head magnetic resonance imaging (MRI) 
abnormalities to an acute encephalopathy.1–5 Although dis-
continuing MTX and supportive measures including the 
addition of corticosteroids and folinic acid frequently result 
in resolution of symptoms, progression to death has been 
reported.1,6,7 Dextromethorphan (DXM), a mu (µ) agonist 
and weak antagonist of the N-methyl d-aspartate (NMDA) 
receptor, may alleviate symptoms of MTX neurotoxicity.4,5,8 
Two adult cancer patients, who verbally consented to publi-
cation of their de-identified medical information, developed 
MTX-related encephalopathy that only improved following 
initiation of treatment with DXM.
Case reports
Case 1
A previously healthy, 91 kg, 24-year-old Caucasian male 
received induction therapy with intrathecal cytarabine, 
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Abstract
Background/Objectives: Neurotoxicity is a serious and sometimes fatal adverse effect that can occur following 
methotrexate treatment. We describe two adult patients with hematological malignancies with methotrexate encephalopathy 
who recovered with dextromethorphan therapy.
Results: Case 1: A 24-year-old male with acute lymphoblastic leukemia developed the acute onset of bilateral facial weakness 
and slurred speech after his first treatment with high-dose intravenous methotrexate. The clinical scenario and a head 
magnetic resonance imaging supported a diagnosis of methotrexate encephalopathy. Treatment with dextromethorphan was 
coincident with recovery. Case 2: A 65-year-old female with recurrent diffuse large B-cell lymphoma was treated with high-
dose intravenous methotrexate. Two weeks after a cycle, she developed hypoactive delirium, marked lethargy, ocular ataxia, 
and a right-sided facial weakness. Within 2 days of starting dextromethorphan, there was improvement with clinical recovery.
Conclusions: These two cases suggest that N-methyl d-aspartate receptor activation by homocysteine may play an important 
role in the pathogenesis of methotrexate neurotoxicity.
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intravenous vincristine, daunorubicin, pegasparaginase, and 
oral prednisone after diagnosis of acute lymphoblastic leuke-
mia in September 2012. In January 2013, he started mainte-
nance intravenous high-dose MTX, dosed at 5 g/m2 for a total 
of 10 g. Prior to the start of MTX, urine alkalinization to a 
pH of 8.5 was achieved and maintained with oral sodium 
bicarbonate. Intravenous folinic acid 50 mg was given 30 h 
after the start of MTX and continued at 25 mg every 6 h until 
plasma MTX concentration at 72 h post MTX dosing was less 
than 0.1 µmol/L. Eight days after receiving the first high dose 
of MTX, the patient developed the acute onset of bilateral 
facial drooping, slurred speech, and lethargy. Over the next 
24 h, he developed left upper extremity weakness. On exami-
nation, the patient was mute and unable to open his mouth to 
command. He had bilateral ptosis, but could open his eyes. 
He required elective intubation for airway protection because 
of progressive oropharyngeal muscle weakness. At this time, 
his MTX plasma concentration was <0.01 µmol/L and a 
complete blood count, comprehensive metabolic laboratory 
panel, and coagulation profile were normal. Neither folate 
nor homocysteine concentrations in cerebrospinal fluid (CSF) 
were measured. A contrast-enhanced head MRI showed sym-
metric, confluent areas of T2 hyperintensity in the bilateral 
deep white matter on the fluid-attenuated inverse recovery 
(FLAIR) sequence. These areas did not enhance and demon-
strated restricted diffusion on the apparent diffusion coeffi-
cient (ADC) map not corresponding to a discrete arterial 
distribution (Figure 1). A repeat MRI of the head performed 
24 h later showed interval worsening of the restricted diffu-
sion within the supratentorial white matter.
He had no improvement in symptoms or neurological 
examination with supportive treatment over the next 48 h. 
On the third day of hospitalization, oral DXM 90 mg (via 
nasogastric (NG) tube) daily was started. After 2 days of 
DXM treatment, there was significant improvement in left 
upper extremity strength. He was extubated on hospital day 
5 with normal mental status and subsequently discharged 
from the hospital on day 6 with a normal neurological exam-
ination and discontinuation of DXM. Repeat MRI showed 
interval resolution of the previously noted abnormalities. 
Subsequent chemotherapy regimen omitted MTX. He is dis-
ease free without recurrence of his neurological symptoms 
3 years after this clinical episode.
Case 2
A 65-year-old Caucasian female presented with a recurrent 
diffuse large B-cell primary central nervous system lym-
phoma (PCNSL) in February 2014 after being in clinical 
remission for 9 years. Her head MRI revealed a new enhanc-
ing left basal ganglia mass. Weighing 93 kg, she started 
treatment with rituximab, MTX (3.5 g/m2, for a total dose of 
6.8 g), procarbazine, and intrathecal MTX (12 mg) in 14-day 
cycles. She completed two cycles uneventfully with standard 
urine alkalinization prior to each dose of MTX as well as 
intravenous folinic acid 50 mg, given 24 h after the start of 
MTX and maintained at 25 mg every 6 h until plasma MTX 
concentration was less than 0.1 µmol/L. The plasma MTX 
concentration was below 0.1 µmol/L at 72 h with each cycle. 
In March 2014, she received her third cycle of MTX but 
clearance was delayed, evidenced by a plasma MTX concen-
tration of 0.23 µmol/L, 72 h post-dosing and elevated liver 
enzymes. Plasma concentrations were below 0.1 µmol/L on 
Day 6 post MTX administration. Two weeks after this third 
dose of high-dose MTX, she presented to the hospital with 
hypoactive delirium. She was disoriented to time, person, or 
place, and her physical examination was notable for marked 
lethargy, ocular ataxia, and a right-sided facial weakness. 
Laboratory studies at this time showed a white blood cell 
count of 12,700/µL with a neutrophil predominance and mild 
thrombocytopenia (95,000/µL), with normal metabolic and 
coagulation profiles. Neither CSF folate nor homocysteine 
Figure 1. Composite fluid-attenuated inverse recovery (FLAIR), T1-weighted post-contrast, and apparent diffusion coefficient 
(ADC) map images from MRI of Case 1 at initial presentation: (a) FLAIR sequence demonstrates symmetric periventricular T2 signal 
hyperintensity, (b) T1 post-contrast shows absence of enhancement, and (c) ADC map indicates presence of restricted diffusion (dark 
signal) within the periventricular white matter corresponding to the distribution of signal alteration on the FLAIR sequence.
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concentrations were measured. Her electroencephalogram 
(EEG) was abnormal with generalized slowing. A repeat 
head MRI revealed near-complete interval resolution of the 
enhancing left basal ganglia mass, but interval development 
of a small area of restricted diffusion at the site of previous 
enhancement in the left basal ganglia (Figure 2).
The patient’s delirium continued for 11 days post admission. 
DXM 60 mg, orally twice daily, was started on day 12 of hos-
pitalization. Within 2 days of starting DXM, marked improve-
ment in her mental status occurred with the patient becoming 
oriented to self, year, and place. She began answering ques-
tions in full sentences and showed the first signs of insight into 
her neurological condition. She continued to improve, being 
discharged from the hospital after 3 days of DXM treatment. 
She did not receive further doses of intravenous or intrathecal 
MTX. She remains without recurrence of neurological symp-
toms or lymphoma more than 3 years after hospital admission.
Conclusion
The appearance of neurological symptoms 2–14 days post 
high-dose MTX administration in both cases is consistent with 
the known time course for subacute MTX neurotoxicity.5,9 
Both cases receive a score of 7 on the Naranjo Probability 
Scale for adverse drug effects, which categorizes the diagno-
sis of MTX encephalopathy as probable.10 MTX-associated 
encephalopathy is usually incapacitating, may follow an 
unpredictable course, and is potentially fatal.1,6,9
The pathogenesis of subacute encephalopathy is postu-
lated to relate to multiple perturbed neuronal biochemical 
processes in addition to a potential direct neurotoxic effect of 
MTX.11 In these cases, the improvement after the adminis-
tration of DXM, an NMDA receptor antagonist, suggests a 
common pathophysiology.
One proposed mechanism of MTX neurotoxicity is the 
reduction of the neuronal concentration of 5-methyltetrahydro-
folate (5-methyl-THF)—necessary to methylate homocysteine 
to methionine resulting in increased concentrations of 
homocysteine.12 Homocysteine has excitatory effects on the 
NMDA receptor, and also causes local and regional neuronal 
death by the activation of NADPH oxidase 2 (NOX2) that 
increases concentrations of superoxide and resultant oxida-
tive stress.13,14 High plasma homocysteine and low pretreat-
ment plasma folate concentrations have been suggested to be 
biomarkers of MTX neurotoxicity;11 however, the develop-
ment of encephalopathy in spite of folinic acid supplementa-
tion in both our cases suggests these plasma biomarkers may 
not be relevant here.
DXM, a lipophilic amine and a NMDA receptor antago-
nist, crosses the blood–brain barrier.15 Theoretically, it may 
attenuate the neurotoxic effects of homocysteine and other 
excitotoxic glutamate analogs in the brain.5,8,16 There are sev-
eral reports of the use and benefit of DXM treatment in the 
symptomatic management of MTX neurotoxicity.4,5,8 Based 
on these reports and the lack of improvement in spite of 
other medical interventions including aggressive folinic acid 
administration, we treated our patients with non-weight-
based dosing of DXM. Both patients had complete resolution 
of symptoms within 48–72 h after starting DXM. While the 
timeframe and course of this recovery is similar to the previ-
ously described time course to resolution of MTX neurotox-
icity symptoms with DXM, a gradual and spontaneous 
resolution of neurotoxicity symptoms with only supportive 
care has also been reported. There is no Food and Drug 
Administration (FDA)-approved indication or dose for DXM 
in the treatment of MTX neurotoxicity, and there are no pro-
spective clinical studies at this time to support a recommen-
dation for its routine use for this indication. A randomized, 
double-blind study of DXM in the prevention and treatment 
of MTX neurotoxicity was recently terminated prior to com-
pletion on account of slow accrual.17 DXM has the potential 
for abuse and addiction;18 however, the short duration of 
treatment using DXM for MTX neurotoxicity may not 
increase this risk. Other drugs with NMDA receptor 
Figure 2. Composite T1-weighted pre-contrast, T1-weighted post-contrast, and apparent diffusion coefficient (ADC) images from MRI 
of Case 2 at onset of delirium (post MTX therapy): (a) T1-weighted pre-contrast image shows a small area of T1 hyperintense signal 
with the left basal ganglia (arrow), (b) No significant enhancement on the T1-weighted post-contrast sequence, and (c) ADC map shows 
restricted diffusion (arrow) at site of T1 hyperintensity in the left basal ganglia.
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antagonist properties including memantine and gabapentin 
may theoretically be used for the treatment of MTX neuro-
toxicity. In vitro and animal studies suggest that memantine is 
able to protect neurons from glutamate analog neurotoxicity; 
however, our review of the literature suggests that DXM has 
the most clinical experience.19,20 Some authors report suc-
cessful rechallenge of pediatric patients with MTX neurotox-
icity without recurrence of symptoms.4 We did not rechallenge 
either of our patients with further MTX treatment and neither 
patient has had a recurrence of their neurological symptoms.
Acknowledgements
The authors would like to thank both patients for their willingness 
to allow use of their medical information in this manuscript.
Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect 
to the research, authorship, and/or publication of this article.
Ethical approval
Our institution does not require ethical approval for reporting indi-
vidual cases or case series.
Funding
The author(s) received no financial support for the research, author-
ship, and/or publication of this article.
Informed consent
Written informed consent was obtained from the patient(s) for their 
anonymized information to be published in this article.
References
 1. Asada Y, Kohga S, Sumiyoshi A, et al. Disseminated necrotiz-
ing encephalopathy induced by methotrexate therapy alone. 
Acta Pathol Jpn 1988; 38(10): 1305–1312.
 2. Ebner F, Ranner G, Slavc I, et al. MR findings in methotrex-
ate-induced CNS abnormalities. AJNR Am J Neuroradiol 
1989; 10(5): 959–964.
 3. Yap SM, MacEneaney P, Ryan C, et al. Alternating hemipa-
resis and orolingual apraxia as manifestations of methotrexate 
neurotoxicity in a paediatric case of acute lymphoblastic leu-
kaemia. BMJ Case Rep 2016; 2016. DOI: 10.1136/bcr-2016-
214677.
 4. Afshar M, Birnbaum D and Golden C. Review of dex-
tromethorphan administration in 18 patients with subacute 
methotrexate central nervous system toxicity. Pediatr Neurol 
2014; 50(6): 625–629.
 5. Drachtman RA, Cole PD, Golden CB, et al. Dextromethorphan 
is effective in the treatment of subacute methotrexate neuro-
toxicity. Pediatr Hematol Oncol 2002; 19(5): 319–327.
 6. Brock S and Jennings HR. Fatal acute encephalomyelitis after 
a single dose of intrathecal methotrexate. Pharmacotherapy 
2004; 24(5): 673–676.
 7. Kay HE, Knapton PJ, O’Sullivan JP, et al. Encephalopathy in 
acute leukaemia associated with methotrexate therapy. Arch 
Dis Child 1972; 47(253): 344–354.
 8. Bettachi CJ, Kamen BA and Cush JJ. Post-methotrexate 
(MTX) CNS toxicity: symptom reduction with dextromethor-
phan. Arthritis Rheum 1999; 42: S164.
 9. Salkade PR and Lim TA. Methotrexate-induced acute 
toxic leukoencephalopathy. J Cancer Res Ther 2012; 8(2): 
292–296.
 10. Naranjo CA, Busto U, Sellers EM, et al. A method for estimat-
ing the probability of adverse drug reactions. Clin Pharmacol 
Ther 1981; 30(2): 239–245.
 11. Vezmar S, Becker A, Bode U, et al. Biochemical and clinical 
aspects of methotrexate neurotoxicity. Chemotherapy 2003; 
49(1–2): 92–104.
 12. Becker A, Vezmar S, Linnebank M, et al. Marked elevation 
in homocysteine and homocysteine sulfinic acid in the cer-
ebrospinal fluid of lymphoma patients receiving intensive 
treatment with methotrexate. Int J Clin Pharmacol Ther 2007; 
45(9): 504–515.
 13. Lipton SA, Kim WK, Choi YB, et al. Neurotoxicity associated 
with dual actions of homocysteine at the N-methyl-D-aspartate 
receptor. Proc Natl Acad Sci U S A 1997; 94(11): 5923–5928.
 14. Boldyrev AA. Homocysteinic acid causes oxidative stress in 
lymphocytes by potentiating toxic effect of NMDA. Bull Exp 
Biol Med 2005; 140(1): 33–37.
 15. Choi DW, Peters S and Viseskul V. Dextrorphan and lev-
orphanol selectively block N-methyl-D-aspartate receptor-
mediated neurotoxicity on cortical neurons. J Pharmacol Exp 
Ther 1987; 242(2): 713–720.
 16. Vijayanathan V, Gulinello M, Ali N, et al. Persistent cogni-
tive deficits, induced by intrathecal methotrexate, are asso-
ciated with elevated CSF concentrations of excitotoxic 
glutamate analogs and can be reversed by an NMDA antago-
nist. Behaviour Brain Res 2011; 225(2): 491–497.
 17. A pilot study of dextromethorphan for the prevention and 
treatment of methotrexate neurotoxicity—full text view—
ClinicalTrials.gov 2017, https://clinicaltrials.gov/ct2/show/
NCT00176553?term=dextromethorphan+methotrexate& 
rank=1
 18. Spangler DC, Loyd CM and Skor EE. Dextromethorphan: a 
case study on addressing abuse of a safe and effective drug. 
Subst Abuse Treat Prevent Policy 2016; 11(1): 22.
 19. Cole PD, Vijayanathan V, Ali NF, et al. Memantine protects 
rats treated with intrathecal methotrexate from develop-
ing spatial memory deficits. Clin Cancer Res 2013; 19(16): 
4446–4454.
 20. Kornhuber J, Weller M, Schoppmeyer K, et al. Amantadine 
and memantine are NMDA receptor antagonists with neuro-
protective properties. J Neural Trans Supplementum 1994; 43: 
91–104.
